Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Date:8/21/2007

BOULDER, Colo. and MONTREAL, Aug. 21 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM), along with its collaborator MethylGene Inc. (TSX: MYG), today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of Hodgkin's lymphoma in the United States. Criteria for designation require that the product be intended for treatment of a condition affecting fewer than 200,000 people in the United States, and the application must include a rationale for the use of the drug in the rare disease or condition.

Preliminary data from a MGCD0103 Phase II monotherapy clinical trial in relapsed and refractory Hodgkin's lymphoma were presented at the American Society of Clinical Oncology 2007 Annual Meeting in June and were included in the application for Orphan Drug Designation. The data demonstrated an objective complete response (CR) plus partial response (PR) rate of 40 percent and a disease control rate (CR + PR + stable disease for > 6 cycles) of 45 percent in a population of 20 evaluable patients that had relapsed disease or were refractory (unresponsive) to all previous treatments, including, in most cases, bone marrow transplantation. Fatigue and gastrointestinal side effects were the most common adverse events and dose modification was effective in many of these patients.

Orphan Drug Designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition. These incentives include, tax credits, research and development grant funding, and reduced filing fees during development or at the time of application for marketing approval. Once approved, th
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014   Lincor Inc. ... patient experience technology to New Jersey ... five-year agreement, CarePoint Health will deploy Lincor,s PatientLINC ... Center, Christ Hospital and Hoboken University Medical Center. ... range of software solutions to help hospitals reach ...
(Date:8/19/2014)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW Bio), ... solid tumor cancers, announced today that the $17.5 million ... has closed.  The three-year notes have a 5% interest ... common stock.  The investors also have an option, exercisable ... 30% of these notes on the same terms. ...
(Date:8/19/2014)... 2014 Research and Markets has ... - Global Strategic Business Report" report to their ... markets for Pharmaceutical Contract Manufacturing in US$ Thousand by ... solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid ... Ointments). The report provides separate comprehensive analytics ...
Breaking Medicine Technology:Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2
(Date:8/20/2014)... most persistent and deadliest infectious diseases in the world, ... Scientists who study tuberculosis have long debated its origins. ... in Africa to seals and sea lions that brought ... Native people there before Europeans landed on the continent. ... a Source of New World Human Tuberculosis," was published ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 As concerns ... of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological ... two U.S. Senators from New York are urging the ... recall of the devices. In a letter dated August ... also implored the agency to seriously consider the testimony ...
(Date:8/20/2014)... stimulates stress responses in adults, researchers at Yerkes ... that the amygdala has an inhibitory effect on ... primates. , The results are published this week ... amygdala is a region of the brain known ... and learning about threats. Alterations in the amygdala ...
(Date:8/20/2014)... HealthDay Reporter TUESDAY, Aug. 19, ... a baby,s immune system is twice as common as once ... says. This is the first evaluation of the effect ... as severe combined immunodeficiency (SCID), or "Bubble Boy" disease, the ... by the boy in the bubble, who was born without ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The main ... 12 per diode panel band perfect spectrum that encompasses the ... most likely to use during photosynthesis. A key point ... is that they almost exclusively reside between 440-480 on the ... the red side of the spectrum. The KIND LED K3 ...
Breaking Medicine News(10 mins):Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2
... , FRIDAY, July 31 (HealthDay News) -- A gene associated ... blindness, has been identified by scientists. , The EphA2 gene ... of damaged proteins in the eye. Expression of the EphA2 ... together and cause the eye lens to become cloudy, resulting ...
... , , , LAWRENCE, ... ), a leading manufacturer of innovative dialysis products, today announced that ... Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009 at ... NxStage,s investor presentation is scheduled for Tuesday, August 11th at 10:00 ...
... , , WOODLAND HILLS, Calif., ... provider of advertising and marketing opportunities for national brands in health ... (NYHRC) chain has agreed to join its network. , ... HCMN will immediately begin installation of its static and digital panel ...
... , CHENNAI, India, July 31 ... Children,s Hospital, the,First Standalone Quaternary Care Paediatric Hospital in the ... ) , The Apollo Children,s ... adolescents up to the age of 16 years all,under one ...
... ... section featuring the latest news and trends from the "wellness" world. , ... Seattle, WA (PRWEB) July 31, ... and sleep-deprived society, alternative medicine and natural health have become a great alternative to ...
... ... to disseminating information on dentistry,s role in the recognition and management of snoring and sleep ... the second month in a row. , ... New York, NY (PRWEB) July 31, 2009 -- Snoring Isn,t Sexy, LLC, a ...
Cached Medicine News:Health News:NxStage to Present at the Canaccord Adams Global Growth Conference 2Health News:Health Club Media Network Adds New York Health & Racquet Club 2Health News:Oscar Award Winner, Dr. A.R. Rahman inaugurates Apollo Children's Hospital - the First Standalone Quaternary Care Paediatric Hospital in the Apollo Hospitals Group 2Health News:Natural Healers Launches "Wellness Community Bulletin" 2Health News:Natural Healers Launches "Wellness Community Bulletin" 3Health News:Natural Healers Launches "Wellness Community Bulletin" 4Health News:SnoringIsntSexy.com Tops 21,000 Site Visits for Second Month in a Row 2
Female Mini-VEST, Front Closure, X-Firm...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Female High Waist Briefs...
Short-Sleeve Bolero for targeted compression in the upper arms, back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Medicine Products: